Zealand Pharma: Survodutide Shows 13.1% Weight Loss in Obesity/Diabetes Trial
Boehringer Ingelheim's survodutide achieved up to 13.1% weight loss and significant improvements in glycemic control during a Phase III trial involving patients with obesity and type 2 diabetes. The results were announced by Zealand Pharma.
Company announcement — No. 1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesCopenhagen, Denmark, October 1, 2026 — Zealand Ph…